Commentary|Podcasts|August 5, 2024

Empty Shelves, Urgent Solutions

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Michael Abrams, Managing Partner at Numerof & Associates discusses:

  • Pharmacy deserts
  • The main factors that are contributing to the closures of both large and independent pharmacies
  • Alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities)
  • Potential long term consequences if closures continue

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.